|WHEN||June 30, 2017 - June 01, 2017 @ 12:30am - 5:00pm|
|WHERE||estancia La Jolla Hotel|
Heart failure remains a major public health problem in the U.S. despite
considerable advances in our understanding of its causes and the
development of new approaches for treatment. To meet the substantial challenges
posed by the growing heart failure population and improve outcomes in
our patients, the 23rd Annual San Diego Heart Failure Symposium has been
structured to highlight important emerging strategies in a series of talks and
discussions aimed at helping the audience discover the best means of utilizing
new approaches in managing patients. Topics that will be covered extend from
preventing heart failure by managing risk factors to treating heart failure in all
its stages. During the Symposium, there will be in-depth discussion of topics
ranging from drugs to devices and non-pharmacologic treatments to invasive
In order to cover the wide range of exciting topics, the expanded Symposium
will start Friday afternoon and extend through late Saturday afternoon. The
Friday sessions will present some of the most stimulating talks of the entire
meeting and will be followed by an outstanding industry sponsored reception
and lecture. The 3rd Annual Stanley Lloyd M.D. lecture at this year’s meeting
will be presented by Dr. Christopher O’Connor, editor in chief JACC:
Heart Failure and President Elect of Heart Failure Society of America. As in
the past, the Symposium offers a unique opportunity to meet and interact
with both your colleagues and the renowned faculty that has been assembled
from UCSD and other institutions. I hope that you will be able to join us for
both the Friday afternoon and Saturday sessions of the 23rd Annual San Diego
Heart Failure Symposium. I very much look forward to seeing you there.
At the conclusion of this program, the participant should be able to:
1. Summarize current and emerging treatments for heart failure, describe new
guideline updates and provide practical information to help in the implementation
of recommended therapies in individual patients.
2. Review strategies for implementing medical and device therapies that will
enhance prevention and lead to improved outcomes in heart failure patients.
3. Define how specific populations including minorities, women and the elderly
respond to various approaches to treating hypertension and heart failure.
The target audience for this activity includes cardiologists, internists, primary
care physicians, nurses and allied healthcare professionals.